Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye Ltd prices offering at US$23 per share

<< Previous

Bullboard Posts

Next >>

Comment by Moondanceon Sep 29, 2023 4:41pm

237 Views

Post# 35662572

RE:RE:RE:RE:RE:Adlai Nortye Ltd prices offering at US$23 per share

Sorry Noteable - this is the comment I was hoping to get more understanding from you on:
re: Adlai pricing their shares at $23
"And if that is the case that then shareholders must really question their trust in ONCY management."

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale